Janssen Announces U.S. FDA Approval of DARZALEX(r) (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

Source :: Plus Company Updates. September 27, 2019
Publication Year :: 2019
Abstract: HORSHAM: Janssen Pharmaceutical Companies of Johnson & Johnson has issued the following press release: - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug [...]

Subjects :: United States. Food and Drug Administration
Johnson & Johnson
Multiple myeloma
Daratumumab
Pharmaceutical industry
Drug approval
Stem cell transplantation
Stem cells
Dexamethasone
Glucocorticoids
Bortezomib
General interest
News, opinion and commentary
Darzalex (Medication)

Tools